chemotherapy Archives -

News/ News/ News/ Oncology/ R&D

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Phil Taylor chemotherapy, Ipsen, Oncology, Onivyde, Servier, small cell lung cancer 0 Comment

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/

News/ News/ Oncology

BeyondSpring faces a tough winter as FDA rejects its lead drug

Phil Taylor BeyondSpring, chemotherapy, fda, Oncology, plinabulin, regulatory 0 Comment

BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it

BeyondSpring faces a tough winter as FDA rejects its lead drug

https://pharmaphorum.com/news/beyondspring-faces-a-tough-winter-as-fda-rejects-its-lead-drug/

Partner content/ Partner Content/ Press releases

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

nrusakova@atrevia.com cancer, Chemo, chemotherapy, clinical trials, patients 0 Comment

Study to improve the life of cancer patients

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

https://pharmaphorum.com/partner-content/a-study-to-avoid-chemotherapy-in-patients-with-early-her-2-breast-cancer/

Turning patient engagment to patient centricity

Oncology/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Being part of the conversation: Turning patient engagement to patient centricity

mike.hammerton@pharmaphorum.com cancer, chemotherapy, patient voices 0 Comment

After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is

Being part of the conversation: Turning patient engagement to patient centricity

https://pharmaphorum.com/oncology/turning-patient-engagement-to-patient-centricity/

News/ News/ News/ Oncology/ R&D

BMS preps filings for leukaemia maintenance therapy CC-486

Phil Taylor acute myeloid leukaemia, Bristol-Myers Squibb, Celgene, chemotherapy, Haematology, Oncology 0 Comment

Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine

BMS preps filings for leukaemia maintenance therapy CC-486

https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/

T-cells attacking cancer cell illustration of microscopic photos

News/ News/ Oncology

Genetic test can predict efficacy of chemotherapy in breast cancer

George Underwood breast cancer, cancer, Cancer Research UK, chemotherapy, genetic testing, Myriad Genetics 0 Comment

Researchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with

Genetic test can predict efficacy of chemotherapy in breast cancer

https://pharmaphorum.com/news/genetic-test-can-predict-efficacy-of-chemotherapy-in-breast-cancer/

Patients/ Views & Analysis/ Views and analysis

From poison to lifeline – how my views on chemotherapy changed as a cancer patient

George Underwood cancer, chemotherapy, patient insights, patients 0 Comment

Cancer survivor Brooke Gant tells us about her experiences with chemotherapy. In 2017, I started off being a

From poison to lifeline – how my views on chemotherapy changed as a cancer patient

https://pharmaphorum.com/views-analysis-patients/from-poison-to-lifeline-how-my-views-on-chemotherapy-changed-as-a-cancer-patient/

Cancer/ ESMO2016/ R&D/ Views and analysis

Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle

Andrew McConaghie breakthrough, chemotherapy, ESMO, lung, Merck, Oncology, pembro, pembrolizumab, small cell, treatment 0 Comment

Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo

Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle

https://pharmaphorum.com/esmo-2016/eye-esmo-day-three-merck-co-wins-big-lung-cancer-battle/

Trending

chemotherapy

Login